#Singapore #oncology #Elephas Biosciences #Invitrocue

Elephas Biosciences Partners with Invitrocue to Advance Personalized Oncology

In a significant leap towards enhancing cancer care, Elephas Biosciences Corporation has announced a strategic commercial partnership with Invitrocue Pte. Ltd. This collaboration aims to extend Elephas' innovative elive™ platform across Southeast Asia, offering new horizons in personalized oncology.

The elive™ platform by Elephas focuses on immunotherapy response prediction through live tissue analysis, addressing the critical need for accurate predictive biomarkers in cancer treatment. Recognized as a major player in personalized oncology, Invitrocue specializes in 3D cell-based cancer models and comprehensive genomic profiling, making them an ideal partner in this venture.

Strengthening Operations in Southeast Asia

The partnership establishes Invitrocue as the commercial distributor for the elive™ platform in Singapore and Malaysia. With its flagship laboratory, Angsana Molecular Diagnostics Laboratory in Singapore, Invitrocue is well-positioned to facilitate access to breakthrough cancer diagnostics across the region. This move represents not only a commercial agreement but also a strategic operational presence in one of the fastest-growing areas in oncology.

Maneesh Arora, the Founder and CEO of Elephas, expressed enthusiasm about the partnership, stating, "Our collaboration with Invitrocue is a pivotal step in making the elive platform accessible through a recognized leader in the field. Together, we can provide researchers and clinicians with actionable insights while expanding the landscape of personalized cancer treatment in Southeast Asia."

A Holistic Approach to Personalized Treatment

The alliance unites three critical methodologies: Invitrocue's Onco-PDO® functional drug testing, its range of genomic profiling tests, and Elephas' elive platform. This integration offers a comprehensive pathway for personalized oncology testing, enhancing the understanding of drug responses and tumor biology, thereby equipping healthcare providers with the tools needed to tailor treatments effectively.

Dr. Steven Fang, CEO of Invitrocue, shared his perspective on the partnership, underscoring a shared commitment to empowering oncologists through deeper insights. By incorporating Elephas' elive platform into their own capabilities, they are setting a solid foundation for advancing personalized oncology research throughout the region.

Impact on Cancer Care

Cancer is a leading health crisis globally, with estimates indicating the number of patients could triple by 2060. Although numerous immunotherapies have emerged, only 20% of patients respond positively, often due to a lack of precise predictive biomarkers. The elive platform seeks to address this issue by evaluating live biopsies' responses to various therapies, preserving essential tumor microenvironments. Its innovative methodology allows real-time assessments of immune responses, potentially transforming treatment pathways.

Both Elephas and Invitrocue emphasize their commitment to improving cancer care. By bringing together cutting-edge technologies and diagnostic capabilities, they aim to pave the way for a future where personalized cancer treatment is not just a concept but a reality.

About Elephas Biosciences

Based in Madison, Wisconsin, Elephas Biosciences is dedicated to tackling critical issues in cancer treatment through its elive platform. This platform, designed for ex vivo analysis of tumor responses to immunotherapies, is poised to revolutionize how treatment efficacy is determined in clinical settings. For further information, please visit Elephas.

About Invitrocue

Invitrocue is at the forefront of life sciences innovation, specializing in developing 3D cell-based models for all solid tumors. Their services facilitate in vitro drug testing through patient-derived organoids, allowing oncologists to customize therapy based on individual patient needs. For more details, visit Invitrocue's official page.